NCT01749969View on ClinicalTrials.gov

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 6, 2013

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Plasma Cell Myeloma
Interventions
DRUG

isatuximab SAR650984

Pharmaceutical form:solution Route of administration: intravenous

DRUG

lenalidomide

Pharmaceutical form:capsules Route of administration: oral

DRUG

dexamethasone

Pharmaceutical form:solution or tablet Route of administration: intravenous or oral

Trial Locations (5)

10021

Investigational Site Number 840005, New York

33612

Investigational Site Number 840001, Tampa

43210

Investigational Site Number 840003, Columbus

63110

Investigational Site Number 840002, St Louis

94117

Investigational Site Number 840004, San Francisco

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY